Lilly Could Grab Diabetes Share From Dow's J&J On Amputation Woes - Investor's Business Daily


Investor's Business Daily

Lilly Could Grab Diabetes Share From Dow's J&J On Amputation Woes
Investor's Business Daily
Eli Lilly's (LLY) Jardiance will likely benefit most after the Food and Drug Administration required Dow component Johnson & Johnson (JNJ) to warn patients of leg and foot amputations associated with diabetes drug Invokana, an analyst said Tuesday.
Johnson & Johnson (JNJ)Zacks.com

all 100 news articles »